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as stent thrombosis. These events are hypothesized to be associated in part with durable
polymers of current DES. The MiStent SES uses a unique combination of components, a
crystalline formulation of sirolimus and a fully absorbable polymer on a thin-strut, cobalt
chromium stent platform. The polymer coating is eliminated from the stent in 45-60 days
with complete absorption in 90 days. Sirolimus is simultaneously released into the
surrounding tissue as a controlled elution.
Methods: The DESSOLVE II clinical trial is a 2:1 randomized study conducted at 26
sites evaluating the MiStent SES for superiority in late lumen loss as compared to the
control stent, the Medtronic Endeavor Sprint (Santa Rosa, CA). Patients with discrete de
novo lesions (2.5-3.5 mm vessel diameter and27 mm length) in native coronary arteries
were acceptable for inclusion in the trial. A total of 183 patients were randomized into
either the MiStent SES or Endeavor Sprint and patients had follow-up at 30-days, 6, 9, and
12-months post-procedure. Angiography was conducted at 9-months with two subgroups:
38 patients imaged using optical coherence tomography (OCT) and 29 patients partici-
pated in endothelial function testing (EFT).
Results: The MiStent SES was superior to Endeavor for the primary endpoint analysis of
late lumen loss. The OCT revealed a mean of 2% uncovered struts with good suppression
on neointimal hyperplasia. EFT demonstrated an overall return of endothelial function
with no incidence of vasoconstriction in either the test or control group. Additional
secondary endpoint data will be presented.
Conclusions: The MiStent SES is an innovative drug eluting stent with sirolimus in a
fully absorbable polymer demonstrating a superior performance as compared to the
Endeavor Sprint DES. OCT shows stent coverage at 9-months with a return of endothelial
function.
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Background: The aim of this first in human study is to assess safety and performance of
the Passeo-18 Lux Paclitaxel releasing PTA balloon (DCB) versus the uncoated
Passeo-18 balloon catheter (POBA) for the treatment of stenosis and occlusion of
femoropopliteal arteries.
Methods: Between October 2010 and August 2011, 60 subjects presenting with stenosis
or occlusion of femoropopliteal arteries were consecutively enrolled in this international,
multicenter, randomized controlled trial under a 1:1 allocation. Primary endpoint of the
study is late lumen loss (LLL) at 6 months assessed by an independent corelab using
quantitative vascular angiography (QCA). Secondary endpoints are binary restenosis (BR)
at 6 months, target lesion revascularization, change in mean ankle brachial index and
Rutherford classification and major adverse events (MAEs) at 6 and 12 months.
Results: Thirty-four men (56.7%) were enrolled in 5 sites. Mean age was 70.710.1
(range 45-90) years. Half of the subjects were treated with the Paclitaxel releasing balloon
(study group) and the other half with the uncoated balloon catheter (control group). The
majority of subjects presented with hypertension (73.3%), followed by smoking (68.3%),
history of PAD (63.3%), hyperlipidemia (61.7%) and diabetes mellitus (33,3%). Almost
two thirds (56.7%) of the subjects were in Rutherford Class 3 and 26.7% were in Class
2. LLL at 6 months was significantly better with 0.50.7mm in the DCB group versus
1.01.0mm in the POBA group (p0.033). Three (11.5%) subjects presented with BR in
the DCB group versus 9 (34.6%) in the POBA group (p0.048). The overall MAE rate
is identical in both groups with 4 (15%) MAEs each. ABI improvement was the same in
both groups from baseline (0.70.2) to 6 months (0.90.2). Clinical outcome in
Rutherford Class was sligthly better in the DCB group with an improvement from
3.00.8 at baseline to 1.61.4 at 6 months versus 2.90.8 to 1.71.3 in the POBA
group.
Conclusions: Six month Results are consistent with previously published data and
confirm the safety and efficacy of DCB for the treatment of symptomatic femoropopliteal
disease. LLL and BR Results were significantly better in the DCB group compared with
POBA.
TCT-586
Impact Of Restenosis Pattern On Angiographical Outcomes After Paclitaxel-
Eluting Balloon Angioplasty For Drug-Eluting Stent Restenosis
Shunsuke Kubo1, Kazushige Kadota1, Seiji Habara1, Takeshi Tada1,
Hiroyuki Tanaka1, Yasushi Fuku1, Naoki Oka1, Harumi Katoh1, Tsuyoshi Goto1,
Kazuaki Mitsudo1
1Kurashiki Central Hospital, Kurashiki, Japan
Background: Previous studies of drug-eluting stent (DES) restenosis have shown that
the morphologic pattern of in-stent restenosis (ISR) was an important predictor of
outcomes after plain balloon angioplasty or repeat DES placement. However, there is no
data available on the relationship between the restenosis pattern and angiographical
outcomes after paclitaxel-eluting balloon (PEB) angioplasty.
Methods: From September 2008 to August 2011, 304 lesions were treated with PEB for
ISR lesions after DES implatation. All of the initial DES were implanted in de novo
lesions (Sirolimus-eluting stent: 156, Paclitaxel-eluting stent: 53, Zotarolimus-eluting
stent: 52, Everolimus-eluting stent: 31, Biolimus-eluting stent: 12). We divided these
lesions into two groups: focal lesions and nonfocal lesions, which were diffuse,
proliferative and total lesions. We investigated the angiographic restenosis pattern and the
restenosis rate at follow-up coronary angiography (CAG). Follow-up CAG was per-
formed at 6 months after procedure.
Results: The angiographical follow-up rate was 91.1% (277 lesions: 99 focal lesions, 178
nonfocal lesions). The binary restenosis rate was 18.2% in focal lesions and 29.2% in
nonfocal lesions (p0.04). The figure shows the restenosis patterns at baseline and
follow-up of the lesions which restenosed for the second time. The recurrent restenosis
pattern at follow-up remained the same in 64.3%, became worse in 7.1% and improved
in 28.6%.
Conclusions: After PEB angioplasty for DES ISR lesions, the morphologic pattern of
ISR is also an important predictor of the outcomes. Most of the recurrent ISR patterns are
the same or better than preprocedural ISR patterns.
Pattern at
baseline Types of change
Pattern at
follow-up
Focal 18 lesions Improved 0 30 lesions
Same 15 lesions
Worse 3 lesions
Diffuse 37 lesions Improved 14 lesions 27 lesions
Same 21 lesions
Worse 2 lesions
Proliferative 7 lesions Improved 1 lesions 7 lesions
Same 6 lesions
Worse 0
Total 8 lesions Improved 6 lesions 6 lesions
Same 2 lesions
Worse 0
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Background: Drug-coated balloons (DCB) have emerged as a potential alternative in
treating in-stent restenosis; however, their role in the treatment of de novo lesions is
unclear. This study aimed to evaluate the safety and efficacy of the second-generation
DIOR DCB as an adjunct to plain old balloon angioplasty (POBA) for the treatment of de
novo coronary lesions.
Methods: Valentines II was designed as a prospective, multicenter, multinational,
Web-based registry. Eligible patients with stable or unstable angina, and/or documented
ischemia on stress testing with de novo lesions of 50% stenosis were prospectively
enrolled. Patients underwent POBA followed by DCB. In cases of suboptimal angio-
graphic success (TIMI flow 3 and/or residual stenosis of 30%), additional bail-out
bare metal stenting (BMS) was left to the operator’s discretion. The primary endpoint was
6-9 months major adverse cardiac events (MACE: all cause death, myocardial infarction,
target vessel revascularization and vessel thrombosis). A subset of patients underwent
angiography follow-up.
Results: 109 lesions in 103 patients were treated. Mean age was 62.6  10.2 years;
79.6% were male. Lesion stenosis at baseline and post treatment was 83.3  9.5% and
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